Tebipenem pivoxil

Unassigned

New Medicines

Urinary tract infection due to multi-drug resistant gram-positive and gram-negative organisms

Information

New molecular entity
Spero Therapeutics
Spero Therapeutics

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
None

Category

Orally active pro-drug of tebipenem, a broad-spectrum carbapenem antibiotic
Complicated UTIs due to resistant gram-negative bacteria are increasing, mainly due to spread of ESBL-producing bacteria and are usually hospital-acquired. Current treatment options are limited due to resistance of existing antibiotics and a lack of new agents. UTIs are estimated to have the highest incidence of all hospital acquired infections at around 35%, and they are most common in patients aged over 60 years.
Urinary tract infection due to multi-drug resistant gram-positive and gram-negative organisms
Oral